Microvast Holdings announces departure of chief financial officer
SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold 174 shares of common stock in a transaction dated March 21, 2025. The shares were sold at a weighted average price of $10.00 per share, totaling $1,740. The transaction occurred as GYRE stock has declined nearly 24% year-to-date, with the current share price at $9.49. InvestingPro analysis suggests the stock is trading below its Fair Value. This transaction was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
Following the sale, Songjiang retains indirect ownership of 2,824,844 shares through a family member. The sale was part of a planned trading strategy, as noted in the filing.
In other recent news, Gyre Therapeutics reported fourth-quarter revenue of $27.87 million, marking a slight increase from the previous year’s $27.1 million for the same period. The company also provided its revenue guidance for 2025, projecting figures between $118 million to $128 million. This estimate falls short of the $135.7 million anticipated by analysts. Gyre’s 2025 outlook assumes the commercial launches of two new products, nintedanib and avatrombopag, which are expected to enhance its existing ETUARY franchise. These products will be introduced in China this year. Despite the revenue guidance being lower than expected, the company remains optimistic about its growth prospects, citing its robust sales and marketing platform. Gyre concluded 2024 with $51.2 million in cash and investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.